384 related articles for article (PubMed ID: 24998423)
21. Molecular surveillance and clinical outcomes of carbapenem-resistant Escherichia coli and Klebsiella pneumoniae infections.
Huang SR; Liu MF; Lin CF; Shi ZY
J Microbiol Immunol Infect; 2014 Jun; 47(3):187-96. PubMed ID: 23200553
[TBL] [Abstract][Full Text] [Related]
22. Carbapenemase-producing Enterobacteriaceae.
Doi Y; Paterson DL
Semin Respir Crit Care Med; 2015 Feb; 36(1):74-84. PubMed ID: 25643272
[TBL] [Abstract][Full Text] [Related]
23. Comparing mortality in patients with carbapenemase-producing carbapenem resistant Enterobacterales and non-carbapenemase-producing carbapenem resistant Enterobacterales bacteremia.
Hovan MR; Narayanan N; Cedarbaum V; Bhowmick T; Kirn TJ
Diagn Microbiol Infect Dis; 2021 Dec; 101(4):115505. PubMed ID: 34399381
[TBL] [Abstract][Full Text] [Related]
24. Antimicrobial treatment and outcomes of critically ill patients with OXA-48like carbapenemase-producing Enterobacteriaceae infections.
Lowman W; Schleicher G
Diagn Microbiol Infect Dis; 2015 Feb; 81(2):138-40. PubMed ID: 25497419
[TBL] [Abstract][Full Text] [Related]
25. Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems.
Fukuchi T; Iwata K; Kobayashi S; Nakamura T; Ohji G
BMC Infect Dis; 2016 Aug; 16(1):427. PubMed ID: 27538488
[TBL] [Abstract][Full Text] [Related]
26. Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae.
Marimuthu K; Ng OT; Cherng BPZ; Fong RKC; Pada SK; De PP; Ooi ST; Smitasin N; Thoon KC; Krishnan PU; Ang MLT; Chan DSG; Kwa ALH; Deepak RN; Chan YK; Chan YFZ; Huan X; Zaw Linn K; Tee NWS; Tan TY; Koh TH; Lin RTP; Hsu LY; Sengupta S; Paterson DL; Perencevich E; Harbarth S; Teo J; Venkatachalam I;
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383670
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and Molecular Characteristics of Carbapenemase-Producing Enterobacteriaceae From Five Hospitals in Korea.
Jeong SH; Kim HS; Kim JS; Shin DH; Kim HS; Park MJ; Shin S; Hong JS; Lee SS; Song W
Ann Lab Med; 2016 Nov; 36(6):529-35. PubMed ID: 27578505
[TBL] [Abstract][Full Text] [Related]
28. Colistin-resistant Enterobacteriaceae bacteraemia: real-life challenges and options.
Tuon FF; Santos TA; Almeida R; Rocha JL; Cieslinsk J; Becker GN; Arend LN
Clin Microbiol Infect; 2016 Feb; 22(2):e9-e10. PubMed ID: 26526298
[No Abstract] [Full Text] [Related]
29. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae.
Russo A; Falcone M; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale PL; Oliver A; Ruiz-Garbajosa P; Gasch O; Gozalo M; Pitout J; Akova M; Peña C; Cisneros JM; Hernández-Torres A; Farcomeni A; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Karaiskos I; de la Calle C; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Rodriguez-Gomez J; Souli M; Bonomo RA; Paterson DL; Carmeli Y; Pascual A; Rodríguez-Baño J; Venditti M;
Int J Antimicrob Agents; 2018 Nov; 52(5):577-585. PubMed ID: 29969692
[TBL] [Abstract][Full Text] [Related]
30. Risk Factors and Molecular Epidemiology of Complicated Intra-Abdominal Infections With Carbapenem-Resistant Enterobacteriaceae: A Multicenter Study in China.
Liu J; Zhang L; Pan J; Huang M; Li Y; Zhang H; Wang R; Zhao M; Li B; Liu L; Gong Y; Bian J; Li X; Tang Y; Lei M; Chen D
J Infect Dis; 2020 Mar; 221(Suppl 2):S156-S163. PubMed ID: 32176797
[TBL] [Abstract][Full Text] [Related]
31. Mortality impact of empirical antimicrobial therapy in ESBL- and AmpC-producing Enterobacteriaceae bacteremia in an Australian tertiary hospital.
Lim CL; Spelman D
Infect Dis Health; 2019 Aug; 24(3):124-133. PubMed ID: 30928569
[TBL] [Abstract][Full Text] [Related]
32. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ
Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
[TBL] [Abstract][Full Text] [Related]
33. Is Carbapenem Therapy Necessary for the Treatment of Non-CTX-M Extended-Spectrum β-Lactamase-Producing Enterobacterales Bloodstream Infections?
Hareza DA; Cosgrove SE; Simner PJ; Harris AD; Bergman Y; Conzemius R; Jacobs E; Beisken S; Tamma PD
Clin Infect Dis; 2024 May; 78(5):1103-1110. PubMed ID: 37972276
[TBL] [Abstract][Full Text] [Related]
34. Molecular epidemiology of carbapenem resistant Enterobacteriaceae in Valle d'Aosta region, Italy, shows the emergence of KPC-2 producing Klebsiella pneumoniae clonal complex 101 (ST101 and ST1789).
Del Franco M; Paone L; Novati R; Giacomazzi CG; Bagattini M; Galotto C; Montanera PG; Triassi M; Zarrilli R
BMC Microbiol; 2015 Nov; 15(1):260. PubMed ID: 26552763
[TBL] [Abstract][Full Text] [Related]
35. [Bacteraemia due to extended-spectrum beta-lactamases (ESBL) and other beta-lactamases (ampC and carbapenemase) producing Enterobacteriaceae: association with health-care and cancer].
García-Gómez M; Guío L; Hernández JL; Vilar B; Pijoán JI; Montejo JM
Rev Esp Quimioter; 2015 Oct; 28(5):256-62. PubMed ID: 26437756
[TBL] [Abstract][Full Text] [Related]
36. Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins.
de Oliveira MS; de Assis DB; Freire MP; Boas do Prado GV; Machado AS; Abdala E; Pierrotti LC; Mangini C; Campos L; Caiaffa Filho HH; Levin AS
Clin Microbiol Infect; 2015 Feb; 21(2):179.e1-7. PubMed ID: 25599940
[TBL] [Abstract][Full Text] [Related]
37. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
Ofer-Friedman H; Shefler C; Sharma S; Tirosh A; Tal-Jasper R; Kandipalli D; Sharma S; Bathina P; Kaplansky T; Maskit M; Azouri T; Lazarovitch T; Zaidenstein R; Kaye KS; Marchaim D
Infect Control Hosp Epidemiol; 2015 Aug; 36(8):981-5. PubMed ID: 25990361
[TBL] [Abstract][Full Text] [Related]
38. Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem.
Oteo J; Ortega A; Bartolomé R; Bou G; Conejo C; Fernández-Martínez M; González-López JJ; Martínez-García L; Martínez-Martínez L; Merino M; Miró E; Mora M; Navarro F; Oliver A; Pascual Á; Rodríguez-Baño J; Ruiz-Carrascoso G; Ruiz-Garbajosa P; Zamorano L; Bautista V; Pérez-Vázquez M; Campos J;
Antimicrob Agents Chemother; 2015; 59(6):3406-12. PubMed ID: 25824224
[TBL] [Abstract][Full Text] [Related]
39. Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital.
Li C; Li Y; Zhao Z; Liu Q; Li B
J Infect Public Health; 2019; 12(1):26-31. PubMed ID: 30145151
[TBL] [Abstract][Full Text] [Related]
40. Extended-Spectrum β-Lactamase- and Carbapenemase-Producing Enterobacteriaceae Isolated from Egyptian Patients with Suspected Blood Stream Infection.
Abdallah HM; Wintermans BB; Reuland EA; Koek A; al Naiemi N; Ammar AM; Mohamed AA; Vandenbroucke-Grauls CM
PLoS One; 2015; 10(5):e0128120. PubMed ID: 26001049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
